Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 23;10:5241. doi: 10.1038/s41598-020-62106-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

ADM and PanIN formation does not require ERBB2. (A) Hematoxylin and eosin staining of WT, ElaC^ER Erbb2^KO, ElaC^ER Kras^G12D and ElaC^ER Erbb2^KO Kras^G12D mice after 1, 3 or 9 weeks of cerulein (W1, W3, W9) treatment. ADM (black arrows) and mild inflammation were present in all mice, and PanIN were detected in ElaC^ER Kras^G12D and ElaC^ER Kras^G12D Erbb2^KO mice. Inflammation and PanIN grade increase with the duration of the treatment. Scale bars = 50 μm. (B) Alcian blue staining of ElaC^ER Kras^G12D and ElaC^ER Erbb2^KO Kras^G12D mice after 1, 3 or 9 weeks of cerulein (W1, W3, W9) treatment. PanIN numbers increased with the duration of treatment but no significant difference was detected between the two genotypes. Scale bars = 50 μm. (C) The ratio of area of Alcian Blue-positive lesions to total pancreatic area increases progressively with the duration of cerulein treatment (W1, W3, W9). No significant difference is observed between the ElaC^ER Kras^G12D mice and ElaC^ER Erbb2^KO Kras^G12D mice. (D) Number (#) of Alcian Blue-positive PanIN relative to total pancreatic area (mm²) in ElaC^ER Kras^G12D and ElaC^ER Erbb2^KO Kras^G12D mice as a function of duration of cerulein treatment (W1, W3, and W9). No significant difference is observed between genotypes.